KLK3 and metastatic prostate carcinoma: As it was shown with the longitudinal CA-125 kinetic in ovarian cancers, the modeled longitudinal PSA kinetics during the 100 days of treatment may represent a novel prognostic factor in patients with metastatic prostate cancers.